MedTrace Logo

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

NCT03424876 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-03-01

No results posted yet for this study

Summary

To compare the efficacy of surgery followed by sunitinib with surgery followed by imatinib in GIST patients with progression on imatinib;To investigate the optimal therapy after surgery in GIST patients with focal or multifocal progression in imatinib

Conditions

Interventions

DRUG

Imatinib 400mg

exposure 400 mg/day or 600mg/day,

DRUG

Sunitinib 37.5Mg Oral Capsule

exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)

Sponsors & Collaborators

  • Peking University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-02
Primary Completion
2018-06-02
Completion
2018-08-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03424876 on ClinicalTrials.gov